Quick-Med wound care tech to enter US trials
This article was originally published in Clinica
Executive Summary
US company Quick-Med Technologies and the University of Florida are to begin clinical trials of their jointly-developed next-generation wound care technology, Nimbus. Shands Hospital, Florida, will be the site for the trials later this year. The products kills bacteria but does not allow the active microbicide to detach and enter the wound. This means that the risk of antibacterial resistance is lower, said Gainesville, Florida-based Quick-Med. The technology is effective against antibiotic-resistant strains of bacteria, such as MRSA and VRE, it added.